By Linetta Koppert, member of the H2O Initiative and Oncological surgeon, clinical epidemiologist, MD PhD at Erasmus MC responds to new data from ASCO We at H2O welcome the presentation of secondary endpoints from the PRO-TECT study related to patient reported outcomes (PROs) and intervention feasibility. These finding, presented as part of the #ASCOPlenarySeries, demonstrate […]
The H2O consortium wishes to reinforce the statements made in the EPFIA Power Up Report highlighting the challenges we must overcome to achieve resilient healthcare systems. If we give patients ways to measure their outcomes in a standardized manner, this will not only improve their communications with their physicians but will also create a body […]
H2O public webinar held last month included the panel entitled “Patient reported outcomes measures in consultations”. Linetta Koppert, MD.PhD.MSc. Surgical Oncologist at Erasmus MC (The Netherlands), Diane Delnoij, Prof. DR. D.M.J. Endowed chair as professor of ‘Governance of healthcare quality and efficiency’ at the Erasmus School of Health Policy & Management and Scientific officer for […]
Read next our summary of Dr Judith Baumhauer, M.D., M.P.F. inspiring keynote “Patient Reported Outcomes: How they influence the care we provide to our patients”. Dr. Baumhauer speech kicked off H2O’s public webinar “Driving a brighter future in healthcare through patient-reported outcomes (PROs): The H2O approach” held online October 5th. Dr. Baumhauer started by referring […]
Our October General Assembly was an important milestone for H2O. During the Assembly, we recognised the considerable progress made towards creating the foundation of the H2O project; the result of many months of hard work across the consortium. The goal for H2O is to create a standardised language for patient reported outcomes (PROs) so that […]
By Professor Tanja Stamm, Co-Lead for H2O and Head of Section for Outcomes Research Center for Medical Statistics, Informatics, and Intelligent Systems Medical University of Vienna The Health Outcomes Observatory (H2O), an IMI funded initiative launched in October 2020, is the first ever unified attempt to collect and incorporate patient-reported outcomes into health care decision-making […]
On June 30th, all Dutch partners of the Health Outcome Observatory (H2O)-project came together for an interactive Oncology Acceleration session. The vision of H2O is to establish patient-centered ethically and legally sound, extensible and permanent national health outcome observatories in four countries. In this session, we evaluated which role every Dutch partner of H2O will […]
Request for Proposal until 31st May – submit a response via email here The H2O project is looking for a public organisation to partner with in order to create the pan-European Observatory that will lead the development and growth of the H2O network. This is a unique opportunity to become part of and shape a truly transformational initiative […]
By Nick Carney, F.Hoffmann-La Roche A recent panel discussion at the DIA Europe 2021 virtual congress chaired by Meni Styliadou (Takeda, H2O Project Leader) titled “Laying the foundation for a value-based, patient-centered, and outcome-driven healthcare system in Europe” provided the opportunity to present the vision of IMI H2O and discuss in project the context of these healthcare […]
The Health Outcomes Observatory (H2O) project kicked off on 1 October 2020 with the aim to equip patients with the tools to measure their outcomes in a standardised way, whilst giving them full control of their data. This is the first-ever attempt at scale to collect and incorporate patient outcomes into healthcare decision making at an individual and population level. And it […]
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/
